Patients diagnosed with migraine according to ICHD-3
Conditions
Interventions
Experimental group:Rimazepam
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years, meeting the International Classification of Headache Disorders (ICHD-3) diagnostic criteria; 2. In the past 3 months, experiencing headaches on at least 15 days per month, with at least 8 days being migraines; 3. Willing to comply with the study protocol and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Participation in other clinical trials within the past 90 days; 2. Suffering from severe mental illnesses (such as schizophrenia or bipolar disorder); 3. Taking other migraine medications that may affect the study results (excluding traditional Chinese medicine).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| monthly migraine days;Freedom from pain at 2 hours;Pain relief at 2 hours; | — |
Secondary
| Measure | Time frame |
|---|---|
| 50% monthly migraine day reduction responder rate;painkillers day;monthly headache days;HIT-6?MIDAS;adverse effect;headache duration;Severity of the headache;Resolution of Most Bothersome Symptom (MBS); | — |
Countries
China
Contacts
Public ContactTan Ge
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed